Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

Tingting Zhang; Weiwei Tian; Shuang Wei; Xinyi Lu; Jing An; Shaolong He; Jie Zhao; Zhilin Gao; Li Li; Ke Lian; Qiang Zhou; Huilai Zhang; Liang Wang; Liping Su; Huicong Kang; Ting Niu; Ailin Zhao; Jing Pan; Qingqing Cai; Zhenshu Xu; Wenming Chen; Hongmei Jing; Peng Li; Wanhong Zhao; Yang Cao; Jianqing Mi; Tao Chen; Yuan Chen; Ping Zou; Veronika Lukacs-Kornek; Christian Kurts; Jian Li; Xiansheng Liu; Qi Mei; Yicheng Zhang; Jia Wei

doi:10.1186/s40164-023-00426-x

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

Tingting Zhang
, Weiwei Tian
, Shuang Wei
, Xinyi Lu
, Jing An
, Shaolong He
, Jie Zhao
, Zhilin Gao
, Li Li
, Ke Lian
, Qiang Zhou
, Huilai Zhang
, Liang Wang
, Liping Su
, Huicong Kang
, Ting Niu
, Ailin Zhao
, Jing Pan
, Qingqing Cai
, Zhenshu Xu

Wenming Chen, Hongmei Jing, Peng Li, Wanhong Zhao, Yang Cao, Jianqing Mi, Tao Chen, Yuan Chen, Ping Zou, Veronika Lukacs-Kornek, Christian Kurts, Jian Li, Xiansheng Liu, Qi Mei, Yicheng Zhang, Jia Wei

Shanxi Medical University
Huazhong University of Science and Technology
Shanxi Bethune Hospital
Tianjin Medical University
Capital Medical University
Sichuan University
Beijing GoBroad Boren Hospital
Sun Yat-Sen University Cancer Center
Fujian Medical University
Peking University
CAS - Guangzhou Institute of Biomedicine and Health
The Second Affiliated Hospital of Xi'an Jiaotong University
Immunotherapy Research Center for Hematologic Diseases of Hubei Province
Shanghai Jiao Tong University
University of Bonn

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

Original language	English
Article number	66
Journal	Experimental Hematology and Oncology
Volume	12
Issue number	1
DOIs	https://doi.org/10.1186/s40164-023-00426-x
State	Published - Dec 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CAR T-cell
COVID-19
Hematological malignancies
Recommendations
SARS-CoV-2
Treatment

Access to Document

10.1186/s40164-023-00426-x

Cite this

Zhang, T., Tian, W., Wei, S., Lu, X., An, J., He, S., Zhao, J., Gao, Z., Li, L., Lian, K., Zhou, Q., Zhang, H., Wang, L., Su, L., Kang, H., Niu, T., Zhao, A., Pan, J., Cai, Q., ... Wei, J. (2023). Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. Experimental Hematology and Oncology, 12(1), Article 66. https://doi.org/10.1186/s40164-023-00426-x

@article{fd568742447f4f5ab303f461ef633442,

title = "Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era",

abstract = "The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.",

keywords = "CAR T-cell, COVID-19, Hematological malignancies, Recommendations, SARS-CoV-2, Treatment",

author = "Tingting Zhang and Weiwei Tian and Shuang Wei and Xinyi Lu and Jing An and Shaolong He and Jie Zhao and Zhilin Gao and Li Li and Ke Lian and Qiang Zhou and Huilai Zhang and Liang Wang and Liping Su and Huicong Kang and Ting Niu and Ailin Zhao and Jing Pan and Qingqing Cai and Zhenshu Xu and Wenming Chen and Hongmei Jing and Peng Li and Wanhong Zhao and Yang Cao and Jianqing Mi and Tao Chen and Yuan Chen and Ping Zou and Veronika Lukacs-Kornek and Christian Kurts and Jian Li and Xiansheng Liu and Qi Mei and Yicheng Zhang and Jia Wei",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1186/s40164-023-00426-x",

language = "英语",

volume = "12",

journal = "Experimental Hematology and Oncology",

issn = "2162-3619",

publisher = "BioMed Central Ltd",

number = "1",

}

Zhang, T, Tian, W, Wei, S, Lu, X, An, J, He, S, Zhao, J, Gao, Z, Li, L, Lian, K, Zhou, Q, Zhang, H, Wang, L, Su, L, Kang, H, Niu, T, Zhao, A, Pan, J, Cai, Q, Xu, Z, Chen, W, Jing, H, Li, P, Zhao, W, Cao, Y, Mi, J, Chen, T, Chen, Y, Zou, P, Lukacs-Kornek, V, Kurts, C, Li, J, Liu, X, Mei, Q, Zhang, Y & Wei, J 2023, 'Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era', Experimental Hematology and Oncology, vol. 12, no. 1, 66. https://doi.org/10.1186/s40164-023-00426-x

TY - JOUR

T1 - Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

AU - Zhang, Tingting

AU - Tian, Weiwei

AU - Wei, Shuang

AU - Lu, Xinyi

AU - An, Jing

AU - He, Shaolong

AU - Zhao, Jie

AU - Gao, Zhilin

AU - Li, Li

AU - Lian, Ke

AU - Zhou, Qiang

AU - Zhang, Huilai

AU - Wang, Liang

AU - Su, Liping

AU - Kang, Huicong

AU - Niu, Ting

AU - Zhao, Ailin

AU - Pan, Jing

AU - Cai, Qingqing

AU - Xu, Zhenshu

AU - Chen, Wenming

AU - Jing, Hongmei

AU - Li, Peng

AU - Zhao, Wanhong

AU - Cao, Yang

AU - Mi, Jianqing

AU - Chen, Tao

AU - Chen, Yuan

AU - Zou, Ping

AU - Lukacs-Kornek, Veronika

AU - Kurts, Christian

AU - Li, Jian

AU - Liu, Xiansheng

AU - Mei, Qi

AU - Zhang, Yicheng

AU - Wei, Jia

PY - 2023/12

Y1 - 2023/12

N2 - The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

AB - The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

KW - CAR T-cell

KW - COVID-19

KW - Hematological malignancies

KW - Recommendations

KW - SARS-CoV-2

KW - Treatment

UR - https://www.scopus.com/pages/publications/85165941915

U2 - 10.1186/s40164-023-00426-x

DO - 10.1186/s40164-023-00426-x

M3 - 文献综述

AN - SCOPUS:85165941915

SN - 2162-3619

VL - 12

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

IS - 1

M1 - 66

ER -

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this